Art. 49 Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 7×
1.

Member States shall ensure that the qualified person referred to in Article 48 fulfils the minimum conditions of qualification set out in paragraphs 2 and 3.

2.

A qualified person shall be in possession of a diploma, certificate or other evidence of formal qualifications awarded on completion of a university course of study, or a course recognized as equivalent by the Member State concerned, extending over a period of at least four years of theoretical and practical study in one of the following scientific disciplines: pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry and technology, biology.

However, the minimum duration of the university course may be three and a half years where the course is followed by a period of theoretical and practical training of a minimum duration of one year and including a training period of at least six months in a pharmacy open to the public, corroborated by an examination at university level.

Where two university courses or two courses recognized by the State as equivalent co-exist in a Member State and where one of these extends over four years and the other over three years, the three-year course leading to a diploma, certificate or other evidence of formal qualifications awarded on completion of a university course or its recognized equivalent shall be considered to fulfil the condition of duration referred to in the second subparagraph in so far as the diplomas, certificates or other evidence of formal qualifications awarded on completion of both courses are recognized as equivalent by the State in question.

The course shall include theoretical and practical study bearing upon at least the following basic subjects:

Experimental physics

General and inorganic chemistry

Organic chemistry

Analytical chemistry

Pharmaceutical chemistry, including analysis of medicinal products

General and applied biochemistry (medical)

Physiology

Microbiology

Pharmacology

Pharmaceutical technology

Toxicology

Pharmacognosy (study of the composition and effects of the natural active substances of plant and animal origin).

Studies in these subjects should be so balanced as to enable the person concerned to fulfil the obligations specified in Article 51.

In so far as certain diplomas, certificates or other evidence of formal qualifications mentioned in the first subparagraph do not fulfil the criteria laid down in this paragraph, the competent authority of the Member State shall ensure that the person concerned provides evidence of adequate knowledge of the subjects involved.

3.

The qualified person shall have acquired practical experience over at least two years, in one or more undertakings which are authorized to manufacture medicinal products, in the activities of qualitative analysis of medicinal products, of quantitative analysis of active substances and of the testing and checking necessary to ensure the quality of medicinal products.

The duration of practical experience may be reduced by one year where a university course lasts for at least five years and by a year and a half where the course lasts for at least six years.

  • Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…61Law

    … лице, което отговаря на условията за квалификация, определени в член 49, параграфи 2 и 3 от Директива 2001/83/ЕО (наричано по-долу …

  • Directive (EU) 2004/27Lawamends

  • Besluit bereiding en aflevering van farmaceutische producten335Law

    … 32, eerste lid, onder c, bedoelde controles geschieden onder leiding en toezicht van een persoon die voldoet aan artikel 49 van richtlijn 2001/83 dan wel op wie artikel 50, eerste lid, van die richtlijn van toepassing is. De in artikel …

  • The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025330Law

    … 2017/1569 in respect of Northern Ireland”; (z2) in paragraph (a) of the definition of “qualified person” for “Article 49 or 50 of Directive 2001/83” substitute “Schedule 7 to the 2012 Regulations”; (z3) after the definition …

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    Articles 41 to 53 of Directive 2001/83 specify the conditions that those national authorisation regimes must satisfy. In particular, the manufacturer in question must make an application and supply a range of information in support of it. …

    25 Jul 2018 · 62017CC0029

  • VwGH 03.07.2012, 2010/10/0224Decision

    3 Jul 2012 · JWT_2010100224_20120703X00

  • VwGH Rechtssatz, 2010/10/0224Decision

    2 Oct 2010 · JWR_2010100224_20120703X01